VNDA — Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA) is a biotechnology company listed on NASDAQ. It is led by Mihael H. Polymeropoulos M.D., based in 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037, with about 533 employees. Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Latest reported VNDA revenue for 2025-09-30 was $56.3M. Net income was -$22.6M. Revenue was up 7.0% from 2025-06-30 to 2025-09-30. VNDA currently screens at market cap $358.4M.

Use this VNDA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VNDA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VNDA SEC filings page. Lician reads the product cache first so this HTML stays unique to Vanda Pharmaceuticals Inc even when a live quote feed is slow.